MEMORIA 2024 - Área 2. Enfermedades Cardiovasculares y Respiratorias

Área 2. Enfermedades Cardiovasculares y Respiratorias

OBJETIVOS CIENTÍFICOS VINCULADOS AL PLAN ESTRATÉGICO

Generar conocimiento científico de excelencia: se presenta un descenso en el número de trabajos publicados aunque hay un incremento importante en el porcentaje de primeros deciles. También conseguimos liderar trabajos de mayor calidad.
Captación de talento científico: se ha producido un breve incremento del personal vinculado a la financiación de los grupos aunque se debe mejorar la captación de ayudas competitivas de recursos humanos.
Dinamizar la captación de recursos: la captación de recursos competitivos también se ha visto mejorada levemente con la consecución de 4 proyectos nacionales. La facturación por ensayos clínicos permance constante.

7 Grupos de Investigación

CARDIOLOGIA CLINICA Y EXPERIMENTAL (CONSOLIDADO)
INVESTIGACIÓN EN PEDIATRÍA (CONSOLIDADO)
TERAPIAS RESPIRATORIAS EN LA INSUFICIENCIA RESPIRATORIA AGUDA (CLÍNICO ASOCIADO)
AEROBIOLOGÍA Y TOXICOLOGÍA AMBIENTAL (EMERGENTE)
FISIOLOGÍA MÉDICA (EMERGENTE)
PROYECTOS DE ENFERMERÍA DE INVESTIGACIÓN E INNOVACIÓN EN CUIDADOS DE SALUD (CLÍNICO ASOCIADO)
INVESTIGACIÓN Y DESARROLLO EN CIRUGÍA CARDIOVASCULAR (CLÍNICO ASOCIADO)

INDICADORES GENERALES

Nº Publicaciones

563.2

Impacto Total

9.39

Impacto Medio

Tipo	Nº Pubs	FI total	FI Medio
Originales	57 (95.0%)	550.5	9.66
Revisiones	3 (5.0%)	12.7	4.23

66.67

Q1%

35.0

D1%

FI >= 15

Tipo	Nº Q1	Nº D1	Nº FI >= 15
Originales	39	21	8
Revisiones	1	0	0

INDICADORES DE LIDERAZGO

20 (33.0%)

Nº Publicaciones

146.8

Impacto Total

7.34

Impacto Medio

	Nº Pubs	FI total	FI Medio
Mujer	8 (40.0%)	54.2	6.78
Hombre	12 (60.0%)	92.6	7.72

60.0

Q1%

30.0

D1%

FI >= 15

	Nº Q1	Nº D1	Nº FI >= 15
Mujer	5	2	1
Hombre	7	4	1

OTROS INDICADORES

26.16

HCP10% (2020-2024)

22.88

HCP10 Liderado% (2020-2024)

5.08

HCP10 Lid. Mujeres% (2020-2024)

3.49

Crown (2020-2024)

76.67

Open Access%

60.0

Col. International%

* Se muestran las 5 especies, los 10 genes y las 20 enfermedades más nombradas. Los valores están normalizados logarítmicamente en base al número de publicaciones.

INDICADORES EVOLUTIVOS

DESTACADAS

Pascual-Figal D, Nunez J, Perez-Martinez MT et al. Colchicine in acutely decompensated heart failure: the COLICA trial. European Heart Journal, 2024, 45, 4826-36, PMID: 39211951, FI: 35.6

Carrillo Mora LM, Tercero Fajardo JJ, Cruz Sepulveda DM, ..., Garcia De Lara J. Septal Ablation to Treat Subaortic Dynamic Obstruction Following Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2024, 84, 411-415, PMID: 39019535, FI: 22.3

Pascual-Figal DA*, Hernandez-Vicente A*, Pastor-Perez F et al. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study. European Journal of Heart Failure, 2024, 26, 776-784, PMID: 38606524, FI: 10.8

Pascual-Figal D, Nunez Villota J, Perez-Martinez MT et al. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA). European Journal of Heart Failure, 2024, 26, 1999-2007, PMID: 38837516, FI: 10.8

Straburzynska-Migaj E, Senni M, Wachter R, ..., Pascual-Figal D*. Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study. Journal of Cardiac Failure, 2024, 30, 425-435, PMID: 37678704, FI: 8.2

LISTADO COMPLETO

Maron MS, Masri A, Nassif ME et al. COLABORADORES: Zhang Y, Yang H, Shao C, ..., Gimeno Blanes JR et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2024, 390, 1849-1861, PMID: 38739079, FI: 78.5

Evangelista A, Galian-Gay L, Guala A, ..., Saura D et al. Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial. Circulation, 2024, 149, 1938-1948, PMID: 38804148, FI: 38.6

Kaski JP, Norrish G, Gimeno Blanes JR et al. Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry. European Heart Journal, 2024, 45, 1443-1454, PMID: 38427064, FI: 35.6

Zuriaga MA, Yu Z, Matesanz N, ..., Pascual-Figal D et al. Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. European Heart Journal, 2024, 45, 4601-4615, PMID: 39212933, FI: 35.6

Caforio ALP, Kaski JP, Gimeno JR et al. Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry. European Heart Journal, 2024, 45, 2548-2569, PMID: 38594778, FI: 35.6

Cabrera-Romero E, Ochoa JP, Barriales-Villa R, ..., Sabater-Molina M et al. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives. Journal of the American College of Cardiology, 2024, 83, 1640-1651, PMID: 38658103, FI: 22.3

Lee MMY, Masri A, Nassif ME, ..., Gimeno JR et al. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial. Jama Cardiology, 2024, 9, 990-1000, PMID: 39230885, FI: 14.1

Fiolet A.T.L., Poorthuis M.H.F., Opstal T.S.J., ..., Pascual-Figal D.A. et al. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials Eclinicalmedicine, 2024, 76, PMID: null, FI: 10.0

Sanchis J, Bueno H, Garcia-Blas S, ..., Marin F et al. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial. Jama Network Open, 2024, 7, e240809, PMID: 38446482, FI: 9.7

de Miguel-Díez J., Núñez Villota J., Santos Pérez S., ..., Pascual Figal D. et al. Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Archivos de Bronconeumologia, 2024, 60, PMID: null, FI: 9.2

Garcia-Pavia P, Palomares JFR, Sinagra G et al. COLABORADORES: Ripoll Vera TV, McDonald TV, Carlos Castillo Dominguez J, ..., Gimeno Blanes JR et al. REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA-Related Dilated Cardiomyopathy. Circulation-Heart Failure, 2024, 17, e011548, PMID: 38979608, FI: 8.4

Aznar F, Negral L, Moreno-Grau S et al. Increased rupture of cypress pollen type due to atmospheric water in central and southeastern Spain. Science of the Total Environment, 2024, 954, 176298, PMID: 39299307, FI: 8.0

Morales E, Prieto-Sanchez MT, Mendiola J, ..., Garcia-Marcos L. Maternal non-compliance with recommended folic acid supplement use alters global DNA methylation in cord blood of newborns: A cohort study. Environmental Research, 2024, 43, 1191-1198, PMID: 38631086, FI: 7.7

Bermudez-Jimenez FJ, Protonotarios A, Garcia-Hernandez S, ..., Munoz-Esparza C et al. Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy. Jacc-Clinical Electrophysiology, 2024, 10, 1178-1190, PMID: 38727660, FI: 7.7

Notario-Barandiaran L, Morales E*, Vioque J et al. Urinary concentrations of non-essential and essential elements during weaning in infants from the NELA cohort in Spain. Environmental Research, 2024, 263, 119989, PMID: 39278582, FI: 7.7

Dominguez F, Uribarri A, Larranaga-Moreira JM, ..., Pascual-Figal D*. Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis. Revista Espanola de Cardiologia, 2024, 77, 667-679, PMID: 38763214, FI: 7.2

Gonzalez-Costello J, Perez-Blanco A, Delgado-Jimenez J, ..., Arribas-Leal JM et al. Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association/ONT/SECCE consensus document. Revista Espanola de Cardiologia, 2024, 77, 69-78, PMID: 37926340, FI: 7.2

Diz-de Almeida S, Cruz R, Luchessi AD, ..., Perez-Tomas ME et al. Novel risk loci for COVID-19 hospitalization among admixed American populations. , 2024, 13, PMID: 39361370, FI: 6.4

Ballester-Servera C, Canes L, Alonso J, ..., Marin F et al. Upregulation of NOR-1 in calcified human vascular tissues: impact on osteogenic differentiation and calcification. Translational Research, 2024, 264, 1-14, PMID: 37690706, FI: 5.9

Amor-Salamanca A, Santana Rodriguez A, Rasoul H, ..., Gimeno-Blanes JR et al. Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction. Circulation-Genomic and Precision Medicine, 2024, 17, e004404, PMID: 38353104, FI: 5.5

de Frutos F, Ochoa JP, Webster G, ..., Sabater-Molina M et al. Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy. Journal of the American Heart Association, 2024, 13, e036208, PMID: 39494569, FI: 5.3

Perez-Jurado LA, Caceres A, Balague-Dobon L et al. COLABORADORES: Abellan J, Acosta-Isaac R, Aguado JM, ..., Perez-Garcia F et al. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2. Communications Biology, 2024, 7, 202, PMID: 38374351, FI: 5.1

Wade U, Pascual-Figal DA, Rabbani F et al. The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study. Nutrients, 2024, 16, PMID: 38674895, FI: 5.0

La Rosa G, Morillo CA, Quintanilla JG, ..., Marin F* et al. Practical approach for atrial cardiomyopathy characterization in patients with atrial fibrillation. Revista Espanola de Cardiologia, 2024, 77, 656-666, PMID: 38428580, FI: 4.9

Gonzalez AA, Visniauskas B, Reverte V et al. Urinary Angiotensinogen Displays Sexual Dimorphism in Non-Diabetic Humans and Mice with Overweight. International Journal of Molecular Sciences, 2024, 25, PMID: 38203807, FI: 4.9

Pastor-Perez FJ, Garrido-Bravo IP, Penafiel-Verdu P et al. Withdrawal of drug therapy in responders to cardiac resynchronization therapy: rationale and design of the REMOVE trial. Revista Espanola de Cardiologia, 2024, 77, 851-858, PMID: 38701881, FI: 4.9

Green N, Chen Y, O'Mahony C, ..., Gimeno JR et al. A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making. European Heart Journal-Quality of Care and Clinical Outcomes, 2024, 10, 285-293, PMID: 37660245, FI: 4.6

Coca A., Bustamante-Munguira E., Fidalgo V., ..., Cánovas S. et al. Evaluating the Effect of periopeRaTIve empaGliflOzin on cardiac surgery associated acute kidney injury: Rationale and design of the VERTIGO study Clinical Kidney Journal, 2024, 17, PMID: null, FI: 4.6

Jurcut R, Barriales-Villa R, Biagini E et al. COLABORADORES: Basso C, Bezzina C, Blom N, ..., Gimeno JR et al. Key priorities for the implementation of the 2023 ESC Guidelines for the Management of Cardiomyopathies in low resource settings. European Heart Journal-Quality of Care and Clinical Outcomes, 2024, qcae103 [pii], PMID: 39657995, FI: 4.6

Gazquez A, Garcia-Serna AM, Hernandez-Caselles T, ..., Martin-Orozco E*, ..., Larque E. Plasma polyamines during pregnancy and their relationships with maternal allergies and the immune response of the neonates. Pediatric Allergy and Immunology, 2024, 35, e14167, PMID: 38860435, FI: 4.5

Lopez-Galvez R*, Rivera-Caravaca JM, Mandaglio-Collados D, ..., Marin F. Endothelial activation, Cell-Cell Interactions, and Inflammatory Pathways in Postoperative Atrial Fibrillation Following Cardiac Surgery. Biomedical Journal, 2024, , 100821, PMID: 39603594, FI: 4.4

Masana L, Diaz Moya G, Perez de Isla L et al. COLABORADORES: Plana N, Andreychuk N, Ruiz Ortiz M, ..., Pascual D et al. Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets. Nutrition Metabolism and Cardiovascular Diseases, 2024, 34, 90-97, PMID: 38092606, FI: 3.7

Pastor Pueyo P, Gambo Ruberte E, Gayan Ordas J, ..., Pascual Figal D et al. Vaccine-carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination. Clinical Research in Cardiology, 2024, 113, 223-234, PMID: 37368015, FI: 3.7

Sanchez-Carballo E, Melgarejo-Meseguer FM, Vijayakumar R, Sanchez-Munoz JJ et al. Reference for Electrocardiographic Imaging-Based T-Wave Alternans Estimation. Ieee Access, 2024, 12, 118510-118524, PMID: 40303849, FI: 3.6

Pérez-Martín J.J., Iofrío de Arce A., Zornoza-Moreno M. et al. The Attitudes of Healthcare Professionals in an Autonomous Community in Spain towards Paediatric Influenza Vaccination Vaccines, 2024, 12, PMID: null, FI: 3.4

Miralles-López J.C., Alvarez-Gutiérrez F.J., Delgado-Romero J., ..., Valverde-Molina J.*. Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus) Journal of Asthma and Allergy, 2024, 17, PMID: null, FI: 3.0

Royo-Villanova M, Moya Sanchez J, Ortin Freire A, De Gea Garcia JH et al. Overcoming Lung Challenges in TA-NRP Assisted Heart Recovery in Donation After the Circulatory Determination of Death. Transplant International, 2024, 37, 13526, PMID: 39629354, FI: 3.0

Hernandez-Lopez MJ, Hernandez-Mendez S, Leal-Costa C et al. Prevalence of Unwanted Loneliness and Associated Factors in People over 65 Years of Age in a Health Area of the Region of Murcia, Spain: HELPeN Project. Journal of Clinical Medicine, 2024, 13, PMID: 39337091, FI: 2.9

Pascual-Figal D.*, Bayes-Genis A. Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review Frontiers in Cardiovascular Medicine, 2024, 11, PMID: null, FI: 2.9

Bayonas-Ruiz A, Munoz-Franco FM, Sabater-Molina M, ..., Bonacasa B*. Concurrent Resistance and Cardiorespiratory Training in Patients with Hypertrophic Cardiomyopathy: A Pilot Study. Journal of Clinical Medicine, 2024, 13, PMID: 38673596, FI: 2.9

Melendo-Viu M, Salguero-Bodes R, Valverde-Gomez M, ..., Sabater-Molina M et al. Hypertrophic cardiomyopathy due to truncating variants in myosin binding protein C: a Spanish cohort. Open Heart, 2024, 11, PMID: 39581692, FI: 2.8

Romero-Tapia SJ, Garcia-Marcos L*. Global burden of pediatric asthma and rhinitis - what we have recently learned from epidemiology. Current Opinion in Allergy and Clinical Immunology, 2024, 24, 177-181, PMID: 38386768, FI: 2.6

Galán Carrillo I., Galbis Martínez L., Martínez V., ..., Guillén Navarro E.*. Multidisciplinary management improves the genetic diagnosis of hereditary kidney diseases in the next generation sequencing (NGS) era Nefrologia, 2024, 44, PMID: null, FI: 2.6

Moreno-Villares JM, Andrade-Platas D, Soria-Lopez M, ..., Valverde-Molina J*. Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial. European Journal of Pediatrics, 2024, 183, 5371-5381, PMID: 39390276, FI: 2.6

Ariza-Solé A., Bermeo J.A., Formiga F., ..., Marín F. et al. Routine invasive strategy and frailty burden in non-ST-segment elevation acute myocardial infarction Journal of Geriatric Cardiology, 2024, 21, PMID: null, FI: 2.6

Sanchez-Solis M, Forno E, Morales E, Garcia-Marcos L. Role of body mass index in unbalanced (dysanaptic) lung growth of healthy infants. Pediatric Pulmonology, 2024, 59, 2939-2946, PMID: 38967254, FI: 2.3

Castelbon Fernandez FJ, Barreda Sanchez M, Arranz Canales E, ..., Guillen Navarro E*. The burden of disease and quality of life in patients with acute hepatic porphyria: COPHASE study. Medicina Clinica, 2024, 162, 103-111, PMID: 37838536, FI: 2.1

Barreda-Bonis A.C., de Bergua Domingo J.M., Galán-Gómez E., Guillén-Navarro E. et al. Expert consensus for the management of patients with achondroplasia in treatment with vosoritide Anales de Pediatria, 2024, 101, PMID: null, FI: 2.1

Álvarez Aldeán J., Álvarez García F.J., Garcés-Sánchez M. et al. Vaccination against seasonal flu in childhood and adolescence. Recommendations of the Advisory Committee on Vaccines and Immunizations of the Spanish Association of Pediatrics (CAV-AEP) for the 2024-2025 season Anales de Pediatria, 2024, 100, PMID: null, FI: 2.1

Álvarez Aldeán J., Álvarez García F.J., de la Calle Fernández-Miranda M. et al. Vaccination in pregnancy. Consensus document of the CAV-AEP and the SEGO Anales de Pediatria, 2024, 100, PMID: null, FI: 2.1

Álvarez García F.J., Iofrío de Arce A., Álvarez Aldeán J. et al. Immunisation schedule of the Pediatric Spanish Association: 2024 recommendations Anales de Pediatria, 2024, 100, PMID: null, FI: 2.1

Miralles-Lopez JC, Carbonell-Martinez A, Zamarro-Parra S, ..., Perez-Fernandez V. Clinical and serological characteristics of patients allergic to LTP. Allergologia et Immunopathologia, 2024, 52, 9-14, PMID: 38970259, FI: 2.1

Pastor-Perez FJ, Veas-Porlan M, Fernandez-Villa N, ..., Pascual-Figal DA*. Semi-quantitative pulmonary congestion score: prevalence and diuretic management implications after heart failure discharge. Revista Clinica Espanola, 2024, 224, 157-161, PMID: 38355098, FI: 1.7

Carrillo-Aleman L., Agamez-Luengas A.A., Guia M., ..., Pascual-Figal D. et al. Effectiveness and safety of non-invasive ventilation in the management of cardiogenic shock Revista Portuguesa de Cardiologia, 2024, 43, PMID: null, FI: 1.6

Zierer A, De Paulis R, Bakhtiary F, ..., Canovas S et al. Sex-related differences among patients undergoing surgical aortic valve replacement-a propensity score matched study. Interdisciplinary Cardiovascular and Thoracic Surgery, 2024, 39, PMID: 39128016, FI: 1.3

AYUDAS CONCEDIDAS EN 2024

TOTAL DE AYUDAS CONCEDIDAS

Nº Ayudas

0.43M €

Financiación

TOTAL DE AYUDAS RECURSOS HUMANOS CONCEDIDAS

Nº Ayudas

0.0M €

Financiación

TOTAL DE AYUDAS PROYECTOS I+D+i CONCEDIDAS

Nº Ayudas Europeas

0.0M €

Financiación Europea

Nº Ayudas Nacionales

0.43M €

Financiación Nacional

Nº Ayudas Regionales

0.0M €

Financiación Regional

TOTAL DE REDES CONCEDIDAS

Nº Ayudas

0.0M €

Financiación

OTRAS AYUDAS COMPETITIVAS CONCEDIDAS (MOVILIDAD, ORGANIZACIÓN DE EVENTOS CIENTÍFICOS, ...)

Nº Ayudas

0.0K €

Financiación

PROYECTOS DE I+D+i Y AYUDAS DE RRHH ACTIVAS EN 2024

TOTAL AYUDAS

RECURSOS HUMANOS

REDES

PROYECTOS INTERNACIONALES

PROYECTOS NACIONALES

PROYECTOS REGIONALES

INICIADA EN 2024

Nº Estudios

Nº Ensayos Clínicos

Nº Producto Sanitario

Nº Estudios Post-Autorización

Nº Otros Estudios

ACTIVOS EN 2024

121

Nº Estudios

Nº Ensayos Clínicos

Nº Producto Sanitario

Nº Estudios Post-Autorización

Nº Otros Estudios

FACTURACIÓN EN 2024

0.57M €

Facturado

Nº Tesis (0 con mención internacional)